Nayzilam

Amnesia, Sedation, Anaesthesia + 14 more
Treatment
1 FDA approval
3 Active Studies for Nayzilam

What is Nayzilam

MidazolamThe Generic name of this drug
Treatment SummaryMidazolam is a short-acting drug used to help patients relax and sleep. It is part of a group of drugs called benzodiazepines and works quickly but doesn’t last long. Midazolam comes in many forms, including oral, rectal, intranasal, intramuscular, and intravenous. It is used to help people feel more relaxed before a medical procedure, like dentistry or surgery. The FDA approved midazolam for different uses in 1985 and added more uses in 2018 and 2019. Midazolam has a low potential for abuse and dependence, so it is
Midazolamis the brand name
image of different drug pills on a surface
Nayzilam Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Midazolam
Midazolam
2000
132

Approved as Treatment by the FDA

Midazolam, also known as Midazolam, is approved by the FDA for 1 uses which include Status Epilepticus (Convulsive) .
Status Epilepticus (Convulsive)

Effectiveness

How Nayzilam Affects PatientsMidazolam is a short-acting medicine that relaxes the central nervous system and reduces anxiety. It works by binding to GABA receptors, which are responsible for controlling certain brain functions. After taking midazolam, adults usually start feeling sedated within 15 minutes, with peak effects occurring 30-60 minutes later. In children, the sedative effects usually begin in 5 minutes and peak in 15-30 minutes. When injected, the effects are felt much faster, with sedation starting in 3-5 minutes. Midazolam can also be used to induce anesthesia, with the effects taking place in about 1.5 minutes
How Nayzilam works in the bodyMidazolam works by enhancing the activity of the neurotransmitter GABA. GABA is a calming chemical in the brain, and midazolam increases its effects. This leads to a sedative effect, muscle relaxation, and can even cause you to forget things. Midazolam acts on special receptors in the body, mainly concentrated in the brain, which allow it to interact with GABA and increase its effects.

When to interrupt dosage

The suggested dosage of Nayzilam is contingent upon the determined condition, for example Induction of General Anaesthesia, Sedation and Seizures. The amount of dosage changes as per the technique of administration featured in the table beneath.
Condition
Dosage
Administration
Anaesthesia
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Central Nervous System Depressants
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Sedation
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
induction of anxiolysis
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Epilepsy
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
preoperative sedation therapy
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Seizures
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
unusual seizure pattern
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Therapeutic procedure
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Anxiolytic therapy therapy
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Therapeutic procedure
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Anxiolysis
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Amnesia
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
induction of Sedation
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
induction of Amnesia
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Status Epilepticus (Convulsive)
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous
Sedation for mechanically-ventilated patients
, 2.0 mg/mL, 0.5 mg/mL, 5.0 mg/mL, 1.0 mg/mL, 10.0 mg/mL, 5.0 mg, 2.5 mg, 7.5 mg, 10.0 mg, 50.0 mg/mL, 3.0 mg
, Oral, Syrup - Oral, Syrup, Injection, solution - Intravenous, Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Buccal, Solution - Buccal, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Troche - Sublingual, Sublingual, Troche, Nasal, Spray - Nasal, Spray, Solution - Intravenous

Warnings

Nayzilam has nine contraindications, so it should not be taken in combination with the afflictions indicated in the following table.Nayzilam Contraindications
Condition
Risk Level
Notes
Glaucoma, Open-Angle
Do Not Combine
Glaucoma, Open-Angle
Do Not Combine
Respiratory Insufficiency
Do Not Combine
Respiratory Distress Syndrome
Do Not Combine
Intrathecal or epidural administration
Do Not Combine
Obstructive Sleep Apnea (OSA)
Do Not Combine
Myasthenia Gravis
Do Not Combine
Severe Hepatic Impairment
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Midazolam may interact with Pulse Frequency
There are 20 known major drug interactions with Nayzilam.
Common Nayzilam Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Midazolam.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Midazolam.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Midazolam.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Midazolam.
Azelastine
Major
Midazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Nayzilam Toxicity & Overdose RiskThe lethal dose of midazolam for rats has been found to be 215mg/kg. Signs of overdose can include drowsiness, confusion, clumsiness, coma, and changes in vital signs. Severe breathing or heart complications can occur, sometimes leading to death or permanent damage. If someone overdoses on midazolam, they should be monitored closely and given resuscitative drugs if necessary. People over 60, those with chronic illnesses or substance abuse problems, and children should take lower doses and be monitored more closely. Midazolam has not been found to be genotoxic and did not affect fertility in rats.

Nayzilam Novel Uses: Which Conditions Have a Clinical Trial Featuring Nayzilam?

12 active clinical trials are presently evaluating the potential of Nayzilam to provide General Anesthesia, Central Nervous System Depressants and induce Amnesia for certain conditions.
Condition
Clinical Trials
Trial Phases
Sedation for mechanically-ventilated patients
0 Actively Recruiting
preoperative sedation therapy
0 Actively Recruiting
Sedation
1 Actively Recruiting
Phase 3
Anaesthesia
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Anxiolytic therapy therapy
0 Actively Recruiting
Epilepsy
0 Actively Recruiting
unusual seizure pattern
0 Actively Recruiting
Seizures
0 Actively Recruiting
Anxiolysis
0 Actively Recruiting
Central Nervous System Depressants
1 Actively Recruiting
Phase 4
Amnesia
1 Actively Recruiting
Phase 1
induction of anxiolysis
0 Actively Recruiting
induction of Sedation
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
induction of Amnesia
0 Actively Recruiting
Status Epilepticus (Convulsive)
0 Actively Recruiting

Nayzilam Reviews: What are patients saying about Nayzilam?

4Patient Review
6/15/2021
Nayzilam for Acute Repetitive Seizures
This medication has been a lifesaver. I have seizure clusters, and before this, I would often wake up in the ER. Now, my husband is able to give me the nasal spray and stop the clusters at home. I usually sleep for a few hours but am pretty clear headed when I wake compared to other emergency meds which either didn’t work or had me sleeping all day and drowsy/confused for days after.
1Patient Review
8/7/2020
Nayzilam for Acute Repetitive Seizures
I found this treatment to be incredibly painful. It felt like someone was shoving a red hot needle down my throat, and I had trouble eating for days afterwards.

Patient Q&A Section about nayzilam

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Nayzilam used for?

"NAYZILAM is a prescription medicine that is used for the short-term treatment of seizure clusters in patients that are at least 12 years old."

Answered by AI

Is Nayzilam a diazepam?

"The drugs Valtoco and Nayzilam are used to treat occasional seizure activity that is different from a patient's usual seizure pattern."

Answered by AI

Is Nayzilam a narcotic?

"Selling or giving away NAYZILAM may harm others and is against the law.

The Controlled Substances Act (CSA) schedules NAYZILAM as a schedule IV substance because it has a low potential for abuse relative to the other controlled substances in schedule IV and because it has a currently accepted medical use in treatment in the United States."

Answered by AI

How quickly does Nayzilam work?

"According to the study, Nayzilam helped the majority of patients to stop a seizure cluster fast and return to function within 90 minutes. Nayzilam may help you to: stop seizure clusters so they don't stop you. with Nayzilam within reach, now you can be ready to treat them quickly."

Answered by AI

Clinical Trials for Nayzilam